ZIEXTENZO

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Spain, UK.

Active ingredients

The drug ZIEXTENZO contains one active pharmaceutical ingredient (API):

1	Pegfilgrastim UNII 3A58010674 - PEGFILGRASTIM
	Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.
	Read more about Pegfilgrastim

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA13	Pegfilgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	6363X, 9514R
CA	Health Products and Food Branch	02497395
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	206-MBE-0721
EE	Ravimiamet	1782907
ES	Centro de información online de medicamentos de la AEMPS	1181327001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	400318
FR	Base de données publique des médicaments	63626633
GB	Medicines & Healthcare Products Regulatory Agency	366099
HK	Department of Health Drug Office	67124
IT	Agenzia del Farmaco	047364017
LT	Valstybinė vaistų kontrolės tarnyba	1086768
NL	Z-Index G-Standaard	15007219
NL	Z-Index G-Standaard, PRK	68756
NZ	Medicines and Medical Devices Safety Authority	20542
PL	Rejestru Produktów Leczniczych	100416364
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65254001
US	FDA, National Drug Code	61314-866